Proteintech, the reference standard for antibodies, announced the acquisition of ChromoTek, a manufacturer of single domain camelid antibodies, also known as nanoantibodies.

ChromoTek is the industry leader in nanoantibodies, high-throughput recombinant reagents used in research activities leading to groundbreaking discoveries. The merger will enable the two companies to take full advantage of growing industry opportunities and more effectively address industry challenges in single cell analysis, super resolution imaging and multiplexing assays.

"Our specialized nanoantibody-based tools seamlessly integrate with Proteintech's comprehensive antibody portfolio that covers a large part of the proteome," says Dr Marion Jung, CEO of ChromoTek. "It is exciting to collaborate with a company that shares our values ​​in terms of reproducibility and quality for the benefit of research and beyond," he adds.

Proteintech CEO Dr Jason Li commented: "This new collaboration will generate considerable value for the market. The availability of manufacturing facilities on three different continents will allow us to better meet the needs of the research market and will have a profound impact on translational science and therapeutic applications ".

Founded in 2002, Proteintech is a leading manufacturer of antibodies, proteins and immunoassays. The company has the largest unique portfolio of self-made antibodies that cover two-thirds of the human proteome. With more than 70,000 publications and a proven specificity, Proteintech offers antibodies and immunoassays for all areas of research. Additionally, Proteintech produces cytokines, growth factors, and other human-expressed proteins that are bioactive and meet current GMP standards. 

ChromoTek is a pioneer in the development and commercialization of innovative reagents based on camelid nanoantibodies. Unlike traditional antibodies, nanoantibodies consist of a single polypeptide chain and are the smallest known antibodies. The company has unique expertise in developing nanoantibodies with the desired affinity, specificity, and format for applications in biomedical research areas where other antibody formats do not work. As the market and product leader in high-throughput reagents, we are proud to contribute to groundbreaking research discoveries around the world.